Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Automated GMP compliant production of [18F]AlF-NOTA-octreotide
Térence Tshibangu, Christopher Cawthorne, Kim Serdons, et al.
EJNMMI Radiopharmacy and Chemistry (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?
Chen Fu, Lifeng Yu, Yuxi Miao, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 13, Iss. 2, pp. 498-516
Open Access | Times Cited: 117
[68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging
Ute Hennrich, Martina Benešová
Pharmaceuticals (2020) Vol. 13, Iss. 3, pp. 38-38
Open Access | Times Cited: 136
[18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients
Elin Pauwels, Frederik Cleeren, Térence Tshibangu, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2020) Vol. 47, Iss. 13, pp. 3033-3046
Closed Access | Times Cited: 75
Preclinical evaluation and pilot clinical study of [18F]AlF-labeled FAPI-tracer for PET imaging of cancer associated fibroblasts
Kongzhen Hu, Junqi Li, Lijuan Wang, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 2, pp. 867-875
Open Access | Times Cited: 62
18F-AlF-NOTA-Octreotide Outperforms68Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study
Elin Pauwels, Frederik Cleeren, Térence Tshibangu, et al.
Journal of Nuclear Medicine (2022) Vol. 64, Iss. 4, pp. 632-638
Open Access | Times Cited: 45
Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling
Mariacristina Failla, Giuseppe Floresta, Vincenzo Abbate
RSC Medicinal Chemistry (2023) Vol. 14, Iss. 4, pp. 592-623
Open Access | Times Cited: 24
18F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use
Hannes Leupe, Stephen Ahenkorah, Jeroen Dekervel, et al.
Journal of Nuclear Medicine (2023) Vol. 64, Iss. 6, pp. 835-841
Open Access | Times Cited: 23
The aluminium-[18F]fluoride revolution: simple radiochemistry with a big impact for radiolabelled biomolecules
Stephen J. Archibald, Louis Allott
EJNMMI Radiopharmacy and Chemistry (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 51
Radiochemistry with {Al18F}2+: Current status and optimization perspectives for efficient radiofluorination by complexation
Sébastien Schmitt, Emmanuel Moreau
Coordination Chemistry Reviews (2023) Vol. 480, pp. 215028-215028
Open Access | Times Cited: 19
Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE
Qing Xie, Teli Liu, Jing Ding, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2021) Vol. 48, Iss. 10, pp. 3129-3140
Closed Access | Times Cited: 33
Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals
Aruna Korde, Renata Mikołajczak, Petra Kolenc Peitl, et al.
EJNMMI Radiopharmacy and Chemistry (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 24
Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours
Leonie Beyer, Astrid Gosewisch, Simon Lindner, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2021) Vol. 48, Iss. 11, pp. 3571-3581
Open Access | Times Cited: 28
Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE
Marcus Unterrainer, Sophie Carina Kunte, Lena M. Unterrainer, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2023) Vol. 50, Iss. 11, pp. 3390-3399
Open Access | Times Cited: 13
Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients
Lennert Boeckxstaens, Elin Pauwels, Vincent Vandecaveye, et al.
EJNMMI Research (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Evaluation of the safety, biodistribution, dosimetry of [18F]AlF-NOTA-LM3 and head-to-head comparison with [68Ga]Ga-DOTATATE in patients with well-differentiated neuroendocrine tumors: an interim analysis of a prospective trial
Meixi Liu, Chao Ren, Haiqiong Zhang, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2024) Vol. 51, Iss. 12, pp. 3719-3730
Closed Access | Times Cited: 4
A practical guide to automating fluorine-18 PET radiochemistry using commercially available cassette-based platforms
Chris Barnes, Manoj S. Nair, Eric O. Aboagye, et al.
Reaction Chemistry & Engineering (2022) Vol. 7, Iss. 11, pp. 2265-2279
Open Access | Times Cited: 18
A clinical observational study of dinutuximab beta as first-line maintenance treatment for patients with high-risk neuroblastoma in China
Xuedi Yu, Suyi Kang, Junjie Ge, et al.
BMC Pediatrics (2025) Vol. 25, Iss. 1
Open Access
Synthesis, Preclinical Characterizations and Imaging Studies of [18F]AlF‐Labeled NY104, a CAIX‐Targeting Diagnostic Agent
Yü Huang, Waisi Eng, Chong Shao, et al.
Journal of Labelled Compounds and Radiopharmaceuticals (2025) Vol. 68, Iss. 4
Open Access
Comparison of inter- and intraobserver agreement between [18F]AlF-NOTA-octreotide and [68Ga]Ga-DOTA-SSA PET/CT
Hannes Leupe, Niloefar Ahmadi Bidakhvidi, Karolien Goffin, et al.
Deleted Journal (2025) Vol. 9, Iss. 1
Open Access
Automatic Production and Preliminary PET Imaging of a New Imaging Agent [18F]AlF-FAPT
Jiawen Huang, Lilan Fu, Kongzhen Hu, et al.
Frontiers in Oncology (2022) Vol. 11
Open Access | Times Cited: 15
3p-C-NETA: A versatile and effective chelator for development of Al18F-labeled and therapeutic radiopharmaceuticals
Stephen Ahenkorah, Erika Murce, Christopher Cawthorne, et al.
Theranostics (2022) Vol. 12, Iss. 13, pp. 5971-5985
Open Access | Times Cited: 15
Direct comparison of [18F]AlF-NOTA-JR11 and [18F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist
Stephen Ahenkorah, Christopher Cawthorne, Erika Murce, et al.
Nuclear Medicine and Biology (2023) Vol. 118-119, pp. 108338-108338
Open Access | Times Cited: 9
Second generation Al18F-labeled D-amino acid peptide for CXCR4 targeted molecular imaging
M. SPAHN, Kaat Luyten, Tom Van Loy, et al.
Nuclear Medicine and Biology (2024) Vol. 132-133, pp. 108906-108906
Closed Access | Times Cited: 3
Automated production of [18F]SiTATE on a Scintomics GRP™ platform for PET/CT imaging of neuroendocrine tumors
Simon Lindner, Marcel Simmet, Franz Josef Gildehaus, et al.
Nuclear Medicine and Biology (2020) Vol. 88-89, pp. 86-95
Closed Access | Times Cited: 23
Recent Advances in the Clinical Translation of Silicon Fluoride Acceptor (SiFA) 18F-Radiopharmaceuticals
Lexi Gower-Fry, Travis Kronemann, Andreas Dorian, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 7, pp. 701-701
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top